mardi 29 octobre 2019

Onco Actu du 29 octobre 2019


1.4 BIOLOGIE - TECHNOS, MODÈLES



The human element: A biotech upstart hopes to carve a path around faulty animal models [EndPoints]











2. ETIOLOGIE



The facts about birth control and cancer risks [Washington Post]











2.11 ETIOLOGIE - ALIMENTATION



Does eating dairy foods increase your risk of prostate cancer? [The Conversation]











2.13 ETIOLOGIE - NDMA



EMA Lays Out Plans for Testing for Nitrosamine Impurities [RAPS]











3.1.1 PRÉVENTION - TABAC - E-CIGS



Characteristics of Patients in a National Outbreak of E-cigarette, or Vaping, Product Use–Associated Lung Injuries — United States, October 2019 [CDC]











Deaths linked to vaping often involved THC products, not nicotine, CDC says [CNN]











4.2 DÉP., DIAG. & PRONO. - GÉNOME



MUTYH: Who should be screened? How should we screen? Who decides? [DNA Exchange]










5.1 TRAITEMENTS - PRÉ-CLINIQUE



Resistance to Targeted Leukemia Drug Lurks in Cells’ “Powerhouse” [Dana-Farber Cancer Institute]











Tumors alone may be linked to cancer patients’ cognitive problems [Ohio State University]











5.10 TRAITEMENTS - ESSAIS



Treating the TOTAL patient: clinical trial reduces relapse [St. Jude Children's Research Hospital]











5.12.11 IMMUNOTHÉRAPIES - PRÉ-CLINIQUE



Teamwork by different T-cell types boosts tumour destruction by immunotherapy [Nature]











5.12.3 IMMUNOTHÉRAPIES-COMBINAISONS



AstraZeneca, on BMS' heels, scores lung cancer win with Imfinzi combos [Fierce Pharma]










AstraZeneca joins Bristol-Myers' run at Merck in lung cancer [Biopharma Dive]











AstraZeneca’s triplet with Imfinzi, treme and chemo works on a key endpoint for frontline lung cancer [EndPoints]











AstraZeneca's combo drug for lung cancer succeeds in late-stage trial [Reuters]











Imfinzi and Imfinzi plus tremelimumab delayed disease progression in Phase III POSEIDON trial for 1st-line treatment of Stage IV non-small cell lung cancer [AstraZeneca]











5.2 PHARMA



Blueprint Medicines Announces FDA Intent to Split Avapritinib New Drug Application into Separate Submissions for PDGFRA Exon 18 Mutant GIST and Fourth-Line GIST [Blueprint]











5.2.3 PHARMA - ÉCONOMIE



Ovarian cancer market set to smash $6.7 billion by 2025 [Pharmafile]











5.9 AACR



Merus Bispecific Antibody MCLA-128 Shows Encouraging Early Clinical Activity in Patients with Cancers Harboring NRG1 Gene Fusions [Merus]











Merus charts early promise for cancer drug targeting NRG1 fusions [Fierce Biotech]











Selumetinib Shows Clinical Benefit in Adult Patients with Neurofibromatosis Type 1-Associated Plexiform Neurofibromas [AACR]











Mixed early data on Agios' AG-270 suggest combo therapy could be way forward [EndPoints]











5.9.8 AACR - BIOTECH



Mirati keeps pace with Amgen in hunt for KRAS cancer drug [Biopharma Dive]











Mirati clears first clinical hurdle in KRAS race against Amgen [Fierce Biotech]










Mirati Therapeutics Presents First Clinical Data Of Phase 1/2 Trial Of MRTX849 At The 2019 AACR-NCI-EORTC International Conference On Molecular Targets And Cancer Therapeutics [Mirati]











MRTX849 Shows Clinical Activity in Patients With KRAS G12C-mutant Solid Cancers [AACR]











Mirati team demonstrates that their KRAS G12C drug is active in NSCLC — but how do they stack up next to Amgen? [EndPoints]











Mirati drug shrinks tumors in some cancer patients in early-stage trial [Reuters]











6. LUTTE CONTRE LES CANCERS



Scientist Led or Mission Oriented – How much does it cost research funders to lead science? [LSE Impact Blog]










6.6 PUBLICATIONS



Careless citations don't just spread scientific myths – they can make them stronger [Nature]











6.7 DMP, BIG DATA & APPLIS



Thinking Inside the Box: five ways the ICR is leading the way with Big Data in cancer research [Institute of Cancer Research]










6.8 COMMUNICATION



Facebook vows strict privacy safeguards as it rolls out preventive-health tool [STAT]